Marín-Hernández Alvaro, Rodríguez-Enríquez Sara, Vital-González Paola A, Flores-Rodríguez Fanny L, Macías-Silva Marina, Sosa-Garrocho Marcela, Moreno-Sánchez Rafael
Instituto Nacional de Cardiología, Departamento de Bioquímica, Juan Badiano no. 1, Colonia Sección XVI, Tlalpan, México, Mexico.
FEBS J. 2006 May;273(9):1975-88. doi: 10.1111/j.1742-4658.2006.05214.x.
Control analysis of the glycolytic flux was carried out in two fast-growth tumor cell types of human and rodent origin (HeLa and AS-30D, respectively). Determination of the maximal velocity (V(max)) of the 10 glycolytic enzymes from hexokinase to lactate dehydrogenase revealed that hexokinase (153-306 times) and phosphofructokinase-1 (PFK-1) (22-56 times) had higher over-expression in rat AS-30D hepatoma cells than in normal freshly isolated rat hepatocytes. Moreover, the steady-state concentrations of the glycolytic metabolites, particularly those of the products of hexokinase and PFK-1, were increased compared with hepatocytes. In HeLa cells, V(max) values and metabolite concentrations for the 10 glycolytic enzyme were also significantly increased, but to a much lesser extent (6-9 times for both hexokinase and PFK-1). Elasticity-based analysis of the glycolytic flux in AS-30D cells showed that the block of enzymes producing Fru(1,6)P2 (i.e. glucose transporter, hexokinase, hexosephosphate isomerase, PFK-1, and the Glc6P branches) exerted most of the flux control (70-75%), whereas the consuming block (from aldolase to lactate dehydrogenase) exhibited the remaining control. The Glc6P-producing block (glucose transporter and hexokinase) also showed high flux control (70%), which indicated low flux control by PFK-1. Kinetic analysis of PFK-1 showed low sensitivity towards its allosteric inhibitors citrate and ATP, at physiological concentrations of the activator Fru(2,6)P2. On the other hand, hexokinase activity was strongly inhibited by high, but physiological, concentrations of Glc6P. Therefore, the enhanced glycolytic flux in fast-growth tumor cells was still controlled by an over-produced, but Glc6P-inhibited hexokinase.
对源自人类和啮齿动物的两种快速生长肿瘤细胞类型(分别为HeLa细胞和AS - 30D细胞)进行了糖酵解通量的控制分析。测定从己糖激酶到乳酸脱氢酶这10种糖酵解酶的最大速度(V(max))发现,大鼠AS - 30D肝癌细胞中己糖激酶(153 - 306倍)和磷酸果糖激酶-1(PFK - 1)(22 - 56倍)的过表达高于正常新鲜分离的大鼠肝细胞。此外,与肝细胞相比,糖酵解代谢物的稳态浓度,尤其是己糖激酶和PFK - 1产物的浓度有所增加。在HeLa细胞中,10种糖酵解酶的V(max)值和代谢物浓度也显著增加,但程度要小得多(己糖激酶和PFK - 1均为6 - 9倍)。基于弹性的AS - 30D细胞糖酵解通量分析表明,产生Fru(1,6)P2的酶(即葡萄糖转运体、己糖激酶、磷酸己糖异构酶、PFK - 1和Glc6P分支)的阻断发挥了大部分通量控制作用(70 - 75%),而消耗性阻断(从醛缩酶到乳酸脱氢酶)表现出其余的控制作用。产生Glc6P的阻断(葡萄糖转运体和己糖激酶)也显示出高通量控制(70%),这表明PFK - 1的通量控制较低。PFK - 1的动力学分析表明,在生理浓度的激活剂Fru(2,6)P2存在下,其对变构抑制剂柠檬酸和ATP的敏感性较低。另一方面,己糖激酶活性受到高浓度但生理浓度的Glc6P的强烈抑制。因此,快速生长肿瘤细胞中增强的糖酵解通量仍由过量产生但受Glc6P抑制的己糖激酶控制。